MTHFR

Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* Product is now available exclusively through Optime Care DEER PARK, Ill., May 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the commercial availability of Betaine Anhydrous for Oral Solution 180 grams for the treatment of homocystinuria. “We are excited to be offering a lower cost alternative1 to Cystadane while still providing full patient and provider support services. We believe the adoption of our product will result in significant financial savings to the U.S. healthcare system and to many patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Betaine Anhydrous is available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions. Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The program will provide prescription fulfillment, insurance benefits investigation, educational support, and qualified patients financial assistance along with other services designed to help eligible patients access treatment. Eton Cares will offer co-pay assistance to allow for $0 co-pays for qualifying patients.* Clinicians seeking to prescribe Betaine Anhydrous can e-prescribe by selecting Optime Care as the pharmacy or fax in a patient referral form to 866-318-2990. Additional product details can be found on the product website, . For questions regarding prescription fulfillment, please contact Optime Care at 1-888-673-0039. 1 accessed March 2023 *Restrictions, limitations, and/or eligibility requirements may apply Cystadane is a registered trademark of Recordati Orphan Drugs SAS IMPORTANT SAFETY INFORMATION Warnings and Precautions Hypermethioninemia in Patients with CBS Deficiency: Betaine Anhydrous may worsen high methionine blood levels and accumulation of excess fluid in the brain has been reported. If you have been told you have CBS deficiency, your doctor will be monitoring your methionine blood levels to see if changes in your diet and dosage are necessary. Adverse Reactions Most common side effects were nausea and gastrointestinal distress, based on a survey of doctors. To report a suspected adverse event related to Betaine Anhydrous, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at or call 1-800-FDA-1088. INDICATIONS AND USAGE Betaine anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood levels. Homocystinuria is a rare genetic disorder in which there is an abnormal accumulation of the amino acid homocysteine in the blood and urine. The following are considered to be homocystinuria disorders: Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect Please see full Prescribing Information for more information. About Eton Pharmaceuticals Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has three FDA approved products in ALKINDI SPRINKLE®, Carglumic Acid tablets for oral suspension 200mg, and Betaine Anhydrous, and four late-stage pipeline candidates under development with dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, ET-400, and ET-600. In addition, the Company receives royalties on three FDA-approved products and is entitled to receive milestone payments on other products. For more information, please visit our website at . Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com 1406-v1

New research identifies genetic cause for hypermobility and hypermobile Ehlers-Danlos syndrome, a novel discovery that may also, for the first time, allow medical professionals to diagnose and treat the connective tissue disorders. Tulane University researchers have discovered a possible genetic cause for hypermobility (commonly known as double-jointedness) and a range of associated connective tissue disorders such as hypermobile Ehlers-Danlos syndrome, according to preliminary findings published in the journal Heliyon. You may know someone with overly flexible joints, a friend or family member who can easily slide into a split or bend limbs to impossible angles. But hypermobility is a more serious condition than being "double-jointed." For those with hypermobile Ehlers-Danlos syndrome (EDS), the same conditions that create fragile connective tissue can cause a range of symptoms that, on the surface, can seem unrelated: physical conditions such as joint pain, chronic fatigue, thin tooth enamel, dizziness, digestive trouble and migraines; and psychiatric disorders, such as anxiety and depression. Women with hypermobile EDS may also be at increased risk for endometriosis or uterine fibroids. Researchers have long struggled to find the cause of hypermobility and hypermobile EDS. Of the 13 subtypes of EDS, hypermobile EDS comprises more than 90% of the cases. But until this study, hypermobile EDS was the only subtype without a known genetic correlate. As a result, symptoms have often been treated individually rather than as the result of a single cause. Researchers at Tulane University School of Medicine have linked hypermobility to a deficiency of folate -- the natural form of vitamin B9 -- caused by a variation of the MTHFR gene. "You've got millions of people that likely have this, and until now, there's been no known cause we've known to treat," said Dr. Gregory Bix, director of the Tulane University Clinical Neuroscience Research Center. "It's a big deal." Those with this genetic variant can't metabolize folate, which causes unmetabolized folate to accumulate in the bloodstream. The folate deficiency may prevent key proteins from binding collagen to the extracellular matrix. This results in more elastic connective tissue, hypermobility, and a potential cascade of associated conditions. The discovery could help doctors more accurately diagnose hypermobility and hypermobile EDS by looking for elevated folate levels in blood tests as well as the MTHFR genetic variant. "Hypermobility is widespread and unfortunately under-recognized," said Dr. Jacques Courseault, medical director of the Tulane Fascia Institute and Treatment Center. "I'm excited about being able to treat the masses where people aren't going their whole lives being frustrated and not getting the treatment they need." Previously, hypermobility could only be diagnosed by the Beighton score, a somewhat controversial physical exam that involves measuring the bend of the spine, fingers and limbs. Combined with a historic lack of acceptance of hypermobility as a distinct body type that requires specialized treatment, the number of people with hypermobility is unclear, though it could comprise more than half the world's population. "Hypermobility is not rare," Courseault said. "Hypermobility is like a Ferrari that requires a lot of maintenance and the best synthetic oil. After knowing a patient's name and date of birth, I think it's prudent for clinicians to know which of these body types they have." Doctors discovered the connection between folate deficiency and the MTHFR gene by working with patients at Tulane's Hypermobility and Ehlers-Danlos Clinic, the only such clinic in the U.S. that focuses on fascia disorders. Blood tests of hypermobile patients who showed signs of associated medical conditions revealed elevated levels of unmetabolized folate. Subsequent tests showed that most of those with elevated folate serum levels had the genetic polymorphism. The good news is a treatment already exists. Methylated folate -- folate that is already processed -- is FDA-approved and widely available. "It's an innocuous treatment," Bix said. "It's not dangerous, and it's a vitamin that can improve people's lives. That's the biggest thing: We know what's going on here, and we can treat it." Though Courseault said more lab research and clinical testing needs to be done, patients who have been treated with folate have shown improvement: less pain, less brain fog, fewer allergies and improved gastrointestinal function. "We've discovered something in medicine that can help, not a small group of people, but potentially many across the world," Courseault said. "This is real, it's been vetted out well and clinically we're noticing a difference."

Innovative wellness brand unveils exclusive prenatal supplement developed specifically for vegan and plant-based diets SANTA MONICA, Calif., Jan. 13, 2023 /PRNewswire/ -- Future Kind, the leading wellness brand best known for their groundbreaking Essential Vegan Vitamin is expanding their family of supplements with their latest launch, Vegan Prenatal Vitamin. The world's first and only prenatal developed specifically for vegan and plant-based diets, tailored with the right amount of B12, Vitamin D, Methylfolate and many other key ingredients. "After my wife became pregnant, we were in a hurry to find the right prenatal product for someone on a plant-based diet. We went into stores, researched online and quickly discovered that the product wasn't available," said Shaun Cunningham, Co-Founder & CEO of Future Kind. "This was quite shocking and we realized this had to change." A prenatal prepares and supports your body for pregnancy and your unique nutritional needs. The Essential Vegan Prenatal Multivitamin was designed to provide moms the nutrients needed during preconception, pregnancy and lactation. The vitamin includes 150mcg of B12, which is in line with the recommended amount for vegans and those on plant-based diets by leading independent nutrition experts like Dr. Michael Greger. Future Kind is also proud to use methylated Folate which ensures about 40% of women with the MTHFR gene variation can absorb it. About Future Kind: Future Kind was founded in 2019 by Aussie brothers, vegans and certified nutritionists Shaun and Eliot. After studying nutrition, they discovered the power of a plant-based diet, but finding the right vegan supplements was difficult and decided to launch Future Kind. Future Kind isn't just for vegans though, and is loved by thousands of people around the world who want to support a company that reflects their values. As a company, they've donated over $30,000 to animal sanctuaries helping to protect neglected and abused animals. Like all of their products, you can expect clean, sustainable and high-quality vegan ingredients. From inception to launch, everything is made in the USA at FDA regulated facilities and 3rd party tested. All deliveries arrive in eco-friendly packaging, typically glass bottles, and 100% carbon neutral deliveries. Learn more at FutureKind.com. Contact: Jackalope Media, Sebastian Urtiz ***@jackalopemediagroup.com Photo(s): Press release distributed by PRLog SOURCE Future Kind